Physician profile
Jane Unaeze
NPI 1447575931
$7,133.25
in general payments reported to CMS, 2019-2025
37 companies · $2,170 in 2025
The $2,170 reported for 2025 was more than what 89% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $295 · 2021: $578 · 2022: $550 · 2023: $1,266 · 2024: $1,989 · 2025: $2,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,415 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,414.84 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,125.38 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Genzyme Corporation | $692.12 | 2020-2025 | |
| Leo Pharma INC. | $667.75 | 2020-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $592.22 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $586.49 | 2023-2025 | Tremfya |
| Ucb, INC. | $409.99 | 2020-2025 | Bimzelx |
| Amgen INC. | $380.36 | 2019-2025 | Otezla, Otezla, Enbrel |
| Lilly USA, LLC | $350.39 | 2019-2024 | Taltz, Olumiant |
| Pfizer INC. | $304.72 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $285.99 | 2020-2025 | Ilumya, Blu-U, Odomzo |
| Incyte Corporation | $254.12 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $208.07 | 2020-2025 | Siliq, Targretin, Duobrii |
| Galderma Laboratories, L.P. | $187.78 | 2019-2025 | Nemluvio |
| Almirall LLC | $143.92 | 2019-2025 | Seysara, Klisyri |
| Celgene Corporation | $115.91 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $104.57 | 2022-2023 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $86.31 | 2021-2025 | |
| Dermavant Sciences, INC. | $71.42 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.68 | 2023-2024 | Spevigo |
| Organon LLC | $64.59 | 2025 | Vtama |
| Paratek Pharmaceuticals, INC. | $63.71 | 2022-2025 | Nuzyra |
| Encore Dermatology INC. | $38.77 | 2019-2020 | |
| Sandoz INC. | $37.89 | 2025 | Hyrimoz |
| Genentech USA, INC. | $33.72 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $32.42 | 2020-2021 | |
| Epi Health, LLC | $27.46 | 2022 | |
| Organogenesis INC. | $25.15 | 2025 | Cygnus Dual |
| Convatec INC. | $24.09 | 2025 | |
| Verrica Pharmaceuticals INC. | $22.18 | 2024 | Ycanth |
| Biofrontera INC. | $20.49 | 2022 | |
| Arcutis Biotherapeutics, INC. | $20.23 | 2025 | Zoryve |
| Nabriva Therapeutics, Plc | $19.06 | 2022 | |
| Botanix Sb INC | $18.68 | 2025 | Sofdra |
| Aclaris Therapeutics, INC. | $14.57 | 2019 | |
| Janssen Scientific Affairs, LLC | $12.37 | 2020 | |
| Mayne Pharma Commercial LLC | $12.36 | 2021 | |
| Integra Lifesciences Corporation | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Unaeze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.